Effective use of fondaparinux in patient with unresponsiveness to nadroparin
What is known and objective Fondaparinux exhibits a similar mechanism of action as LMWH. Since both of these drugs bind to antithrombin and increase its affinity to factor Xa, fondaparinux is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance. Case summary W...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical pharmacy and therapeutics 2021-04, Vol.46 (2), p.539-542 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 542 |
|---|---|
| container_issue | 2 |
| container_start_page | 539 |
| container_title | Journal of clinical pharmacy and therapeutics |
| container_volume | 46 |
| creator | Hartinger, Jan Miroslav Svobodová, Alžběta Malíková, Ivana Šachl, Robert Slanař, Ondřej |
| description | What is known and objective
Fondaparinux exhibits a similar mechanism of action as LMWH. Since both of these drugs bind to antithrombin and increase its affinity to factor Xa, fondaparinux is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance.
Case summary
We report on a case of effective anticoagulation using fondaparinux following total unresponsiveness to high doses of nadroparin administered twice daily, as confirmed via repeated anti‐Xa measurements. The antithrombin levels were within the normal range.
What is new and conclusion
To the best of our knowledge, this is the first report of the effective use of fondaparinux in the case of unresponsiveness to LMWH.
Fondaparinux exhibits a similar mechanism of action as LMWH, therefore it is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance. We report on a case of effective anticoagulation using fondaparinux following total unresponsiveness to high doses of nadroparin. To the best of our knowledge, this is the first time that effective anticoagulation was attained via the application of fondaparinux but not LMWH. |
| doi_str_mv | 10.1111/jcpt.13328 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1111_jcpt_13328</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2501873579</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3608-9c63dcf68f8cf13d19b8b97ff74552b5d82fc6a4c989fdd3ec8707189995c2303</originalsourceid><addsrcrecordid>eNqNkMtOwzAQRS0EgvLY8AHIEjtQwI86tpco4qlKsChrK3FskQrsYDuU_j2mKSwRs5lZnDszOgAcY3SBc10udJ8uMKVEbIEJpiUrCMdoG0wQKWUx5YTvgf0YFwihkhO6C_Yyy7nEYgJm19YanboPA4dooLfQetfWfR06N3zCzsG-Tp1xCS679AIHF0zsvYs54EyMMHno6jb4deAQ7Nj6NZqjTT8AzzfX8-qumD3e3ldXs0LTEolC6pK22pbCCm0xbbFsRCO5tXzKGGlYK4jVZT3VUkjbttRowRHHQkrJNKGIHoDTcW8f_PtgYlILPwSXTyrCEBacMi4zdTZSOvgYg7GqD91bHVYKI_UtTn2LU2txGT7ZrByaN9P-oj-mMnA-AkvTeBt1dqLNL5bVMslKInmeEM60-D9ddSk79q7yg0s5ijfR7tWs_vhZPVRP8_H7L5Hwmc4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2501873579</pqid></control><display><type>article</type><title>Effective use of fondaparinux in patient with unresponsiveness to nadroparin</title><source>Access via Wiley Online Library</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Hartinger, Jan Miroslav ; Svobodová, Alžběta ; Malíková, Ivana ; Šachl, Robert ; Slanař, Ondřej</creator><creatorcontrib>Hartinger, Jan Miroslav ; Svobodová, Alžběta ; Malíková, Ivana ; Šachl, Robert ; Slanař, Ondřej</creatorcontrib><description>What is known and objective
Fondaparinux exhibits a similar mechanism of action as LMWH. Since both of these drugs bind to antithrombin and increase its affinity to factor Xa, fondaparinux is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance.
Case summary
We report on a case of effective anticoagulation using fondaparinux following total unresponsiveness to high doses of nadroparin administered twice daily, as confirmed via repeated anti‐Xa measurements. The antithrombin levels were within the normal range.
What is new and conclusion
To the best of our knowledge, this is the first report of the effective use of fondaparinux in the case of unresponsiveness to LMWH.
Fondaparinux exhibits a similar mechanism of action as LMWH, therefore it is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance. We report on a case of effective anticoagulation using fondaparinux following total unresponsiveness to high doses of nadroparin. To the best of our knowledge, this is the first time that effective anticoagulation was attained via the application of fondaparinux but not LMWH.</description><identifier>ISSN: 0269-4727</identifier><identifier>EISSN: 1365-2710</identifier><identifier>DOI: 10.1111/jcpt.13328</identifier><identifier>PMID: 33277918</identifier><language>eng</language><publisher>HOBOKEN: Wiley</publisher><subject>Anticoagulants ; anticoagulation ; Antithrombin ; heparin resistance ; Life Sciences & Biomedicine ; low molecular weight heparin ; pentasaccharide ; Pharmacology & Pharmacy ; Science & Technology</subject><ispartof>Journal of clinical pharmacy and therapeutics, 2021-04, Vol.46 (2), p.539-542</ispartof><rights>2020 John Wiley & Sons Ltd</rights><rights>2020 John Wiley & Sons Ltd.</rights><rights>Copyright © 2021 John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>1</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000595629700001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c3608-9c63dcf68f8cf13d19b8b97ff74552b5d82fc6a4c989fdd3ec8707189995c2303</citedby><cites>FETCH-LOGICAL-c3608-9c63dcf68f8cf13d19b8b97ff74552b5d82fc6a4c989fdd3ec8707189995c2303</cites><orcidid>0000-0002-6320-3273 ; 0000-0002-5357-7562</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjcpt.13328$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjcpt.13328$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,39263,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33277918$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hartinger, Jan Miroslav</creatorcontrib><creatorcontrib>Svobodová, Alžběta</creatorcontrib><creatorcontrib>Malíková, Ivana</creatorcontrib><creatorcontrib>Šachl, Robert</creatorcontrib><creatorcontrib>Slanař, Ondřej</creatorcontrib><title>Effective use of fondaparinux in patient with unresponsiveness to nadroparin</title><title>Journal of clinical pharmacy and therapeutics</title><addtitle>J CLIN PHARM THER</addtitle><addtitle>J Clin Pharm Ther</addtitle><description>What is known and objective
Fondaparinux exhibits a similar mechanism of action as LMWH. Since both of these drugs bind to antithrombin and increase its affinity to factor Xa, fondaparinux is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance.
Case summary
We report on a case of effective anticoagulation using fondaparinux following total unresponsiveness to high doses of nadroparin administered twice daily, as confirmed via repeated anti‐Xa measurements. The antithrombin levels were within the normal range.
What is new and conclusion
To the best of our knowledge, this is the first report of the effective use of fondaparinux in the case of unresponsiveness to LMWH.
Fondaparinux exhibits a similar mechanism of action as LMWH, therefore it is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance. We report on a case of effective anticoagulation using fondaparinux following total unresponsiveness to high doses of nadroparin. To the best of our knowledge, this is the first time that effective anticoagulation was attained via the application of fondaparinux but not LMWH.</description><subject>Anticoagulants</subject><subject>anticoagulation</subject><subject>Antithrombin</subject><subject>heparin resistance</subject><subject>Life Sciences & Biomedicine</subject><subject>low molecular weight heparin</subject><subject>pentasaccharide</subject><subject>Pharmacology & Pharmacy</subject><subject>Science & Technology</subject><issn>0269-4727</issn><issn>1365-2710</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><recordid>eNqNkMtOwzAQRS0EgvLY8AHIEjtQwI86tpco4qlKsChrK3FskQrsYDuU_j2mKSwRs5lZnDszOgAcY3SBc10udJ8uMKVEbIEJpiUrCMdoG0wQKWUx5YTvgf0YFwihkhO6C_Yyy7nEYgJm19YanboPA4dooLfQetfWfR06N3zCzsG-Tp1xCS679AIHF0zsvYs54EyMMHno6jb4deAQ7Nj6NZqjTT8AzzfX8-qumD3e3ldXs0LTEolC6pK22pbCCm0xbbFsRCO5tXzKGGlYK4jVZT3VUkjbttRowRHHQkrJNKGIHoDTcW8f_PtgYlILPwSXTyrCEBacMi4zdTZSOvgYg7GqD91bHVYKI_UtTn2LU2txGT7ZrByaN9P-oj-mMnA-AkvTeBt1dqLNL5bVMslKInmeEM60-D9ddSk79q7yg0s5ijfR7tWs_vhZPVRP8_H7L5Hwmc4</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Hartinger, Jan Miroslav</creator><creator>Svobodová, Alžběta</creator><creator>Malíková, Ivana</creator><creator>Šachl, Robert</creator><creator>Slanař, Ondřej</creator><general>Wiley</general><general>Hindawi Limited</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><orcidid>https://orcid.org/0000-0002-6320-3273</orcidid><orcidid>https://orcid.org/0000-0002-5357-7562</orcidid></search><sort><creationdate>202104</creationdate><title>Effective use of fondaparinux in patient with unresponsiveness to nadroparin</title><author>Hartinger, Jan Miroslav ; Svobodová, Alžběta ; Malíková, Ivana ; Šachl, Robert ; Slanař, Ondřej</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3608-9c63dcf68f8cf13d19b8b97ff74552b5d82fc6a4c989fdd3ec8707189995c2303</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anticoagulants</topic><topic>anticoagulation</topic><topic>Antithrombin</topic><topic>heparin resistance</topic><topic>Life Sciences & Biomedicine</topic><topic>low molecular weight heparin</topic><topic>pentasaccharide</topic><topic>Pharmacology & Pharmacy</topic><topic>Science & Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hartinger, Jan Miroslav</creatorcontrib><creatorcontrib>Svobodová, Alžběta</creatorcontrib><creatorcontrib>Malíková, Ivana</creatorcontrib><creatorcontrib>Šachl, Robert</creatorcontrib><creatorcontrib>Slanař, Ondřej</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><jtitle>Journal of clinical pharmacy and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hartinger, Jan Miroslav</au><au>Svobodová, Alžběta</au><au>Malíková, Ivana</au><au>Šachl, Robert</au><au>Slanař, Ondřej</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effective use of fondaparinux in patient with unresponsiveness to nadroparin</atitle><jtitle>Journal of clinical pharmacy and therapeutics</jtitle><stitle>J CLIN PHARM THER</stitle><addtitle>J Clin Pharm Ther</addtitle><date>2021-04</date><risdate>2021</risdate><volume>46</volume><issue>2</issue><spage>539</spage><epage>542</epage><pages>539-542</pages><issn>0269-4727</issn><eissn>1365-2710</eissn><abstract>What is known and objective
Fondaparinux exhibits a similar mechanism of action as LMWH. Since both of these drugs bind to antithrombin and increase its affinity to factor Xa, fondaparinux is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance.
Case summary
We report on a case of effective anticoagulation using fondaparinux following total unresponsiveness to high doses of nadroparin administered twice daily, as confirmed via repeated anti‐Xa measurements. The antithrombin levels were within the normal range.
What is new and conclusion
To the best of our knowledge, this is the first report of the effective use of fondaparinux in the case of unresponsiveness to LMWH.
Fondaparinux exhibits a similar mechanism of action as LMWH, therefore it is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance. We report on a case of effective anticoagulation using fondaparinux following total unresponsiveness to high doses of nadroparin. To the best of our knowledge, this is the first time that effective anticoagulation was attained via the application of fondaparinux but not LMWH.</abstract><cop>HOBOKEN</cop><pub>Wiley</pub><pmid>33277918</pmid><doi>10.1111/jcpt.13328</doi><orcidid>https://orcid.org/0000-0002-6320-3273</orcidid><orcidid>https://orcid.org/0000-0002-5357-7562</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-4727 |
| ispartof | Journal of clinical pharmacy and therapeutics, 2021-04, Vol.46 (2), p.539-542 |
| issn | 0269-4727 1365-2710 |
| language | eng |
| recordid | cdi_crossref_primary_10_1111_jcpt_13328 |
| source | Access via Wiley Online Library; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Anticoagulants anticoagulation Antithrombin heparin resistance Life Sciences & Biomedicine low molecular weight heparin pentasaccharide Pharmacology & Pharmacy Science & Technology |
| title | Effective use of fondaparinux in patient with unresponsiveness to nadroparin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T22%3A47%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effective%20use%20of%20fondaparinux%20in%20patient%20with%20unresponsiveness%20to%20nadroparin&rft.jtitle=Journal%20of%20clinical%20pharmacy%20and%20therapeutics&rft.au=Hartinger,%20Jan%20Miroslav&rft.date=2021-04&rft.volume=46&rft.issue=2&rft.spage=539&rft.epage=542&rft.pages=539-542&rft.issn=0269-4727&rft.eissn=1365-2710&rft_id=info:doi/10.1111/jcpt.13328&rft_dat=%3Cproquest_cross%3E2501873579%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2501873579&rft_id=info:pmid/33277918&rfr_iscdi=true |